Selective JAK2 Inhibition OB756 Shows Promise in Hydroxyurea/Interferon‑Intolerant or -Resistant Essential Thrombocythemia
Posted inHematology-Oncology news

Selective JAK2 Inhibition OB756 Shows Promise in Hydroxyurea/Interferon‑Intolerant or -Resistant Essential Thrombocythemia

A Phase II multicenter study reports that OB756, a selective JAK2 inhibitor, is active and reasonably well tolerated in hydroxyurea- or interferon-intolerant/resistant essential thrombocythemia, producing platelet and leukocyte control, spleen volume reduction, symptom improvement and reductions in JAK2 V617F allele burden.
Two-thirds of ACL-injured Patients Avoid Surgery at 2 Years: Nationwide Registry Shows Rehab-first Strategy Often Works but Younger, Pivoting-sport Athletes and Meniscal Tears Predict Delayed Reconstruction
Posted innews Orthopedics Rehabilitation Medicine

Two-thirds of ACL-injured Patients Avoid Surgery at 2 Years: Nationwide Registry Shows Rehab-first Strategy Often Works but Younger, Pivoting-sport Athletes and Meniscal Tears Predict Delayed Reconstruction

A Norwegian registry study reports that 63% of patients with primary ACL injury initially managed non‑operatively remained non‑operative at two years; younger age, participation in pivoting sports and baseline meniscal injury increased risk of delayed ACL reconstruction, while 2‑year KOOS scores were similar.
SGLT2 Inhibitors Linked to Lower Parkinson’s Disease Risk Than Metformin in Type 2 Diabetes: Large Real‑World TriNetX Study Signals Class Neuroprotection
Posted inDiabetes & Endocrinology Neurology news

SGLT2 Inhibitors Linked to Lower Parkinson’s Disease Risk Than Metformin in Type 2 Diabetes: Large Real‑World TriNetX Study Signals Class Neuroprotection

A 20‑year TriNetX analysis of 913,428 T2DM patients found SGLT2 inhibitor use associated with a 28% lower Parkinson’s disease risk versus metformin (aHR 0.72), suggesting possible superior neuroprotection and prompting need for prospective confirmation.